-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 20% of pediatric acute myeloid leukemia (AML) cases have chromosomal recombination involving the KMT2A gene (KMT2A-r) .
About 20% of pediatric acute myeloid leukemia (AML) cases have chromosomal reorganization involving the KMT2A gene (KMT2A-r)
This study aimed to evaluate the effect of CD33-targeted drug gemtuzumab ozogamicin (GO) on the survival and prognosis of children with KMT2A-r AML enrolled in the Childhood Oncology Group Trial AAML0531 (NCT01407757).
child
The researchers identified KMT2A-r AML patients and described their clinical characteristics.
EFS and OS in patients with or without KMT2A-r or GO exposure
EFS and OS in patients with or without KMT2A-r or GO exposureAmong 1022 AML patients, 215 (21%) carried KMT2A-r .
There were 215 (21%) who carried KMT2A-r and 215 (21%) who carried KMT2A-r for 5-year EFS and OS were 38% and 58%, respectively.
EFS in high-risk and non-high-risk KMT2A-r subgroups
EFS in high-risk and non-high-risk KMT2A-r subgroupsFor patients with KMT2A-r AML who achieved complete remission, GO treatment was used with lower RR (GO vs non-GO: 40% vs 66%; p=0.
For complete remission KMT2A-r-type of AML patients, the use of GO therapy with lower RR and improved 5-year DFS related
Whether there is GO exposure and the risk of recurrence in HSCT patients
Whether there is GO exposure and the risk of recurrence in HSCT patientsFor patients who underwent HSCT, previous GO exposure was associated with a reduction in recurrence (5-year RR: 28% vs 73%; p=0.
For patients who underwent HSCT, previous GO exposure was associated with a reduction in recurrence (5-year RR: 28% vs 73%; p=0.
Adding gemtuzumab ozogamicin to conventional chemotherapy regimens can improve the prognosis of patients with KMT2A-r AML, and consolidation by HSCT can further improve the efficacy of GO.
Original source:
Pollard Jessica A,Guest Erin,Alonzo Todd A et al.
KMT2AGemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric -Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531
in this message
